SCHEMBL26239208

SCHEMBL26239208

CC(NC(=O)c1cc(OCCN(C)CCc2ccc(CS(=N)(=O)O)cc2)ccc1NS(C)(=O)=O)C(=O)OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.44
DRD3 P35462 2/20 0.44
CACNA1F O60840 1/20 0.44
CHRM2 P08172 1/20 0.44
ACHE P22303 1/20 0.44
AGTR1 P30556 1/20 0.44
CACNA1D Q01668 1/20 0.44
CACNA1S Q13698 1/20 0.44
CACNA1C Q13936 1/20 0.44
MCL1 Q07820 1/20 0.39
BCL2A1 Q16548 1/20 0.39
HTT P42858 1/20 0.38
LTA4H P09960 2/20 0.36
ATM Q13315 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26239203 0.85 KCNH2 (0.44) KCNH2DRD3CACNA1FCHRM2ACHE
SCHEMBL26239221 0.80 KCNH2 (0.46) KCNH2DRD3CACNA1FCHRM2ACHE
SCHEMBL26239199 0.73 KCNH2 (0.80) KCNH2DRD3CACNA1FCHRM2ACHE
SCHEMBL26239293 0.68 KCNH2 (0.71) KCNH2DRD3CACNA1FCHRM2ACHE
SCHEMBL26239216 0.66 KCNH2 (0.46) KCNH2DRD3CACNA1FCHRM2ACHE
Dofetilide SCHEMBL16135 0.64 KCNH2 (1.00) KCNH2DRD3CACNA1FCHRM2ACHE
Dofetilide SCHEMBL6102734 0.64 KCNH2 (1.00) KCNH2DRD3CACNA1FCHRM2ACHE
SCHEMBL16804690 0.63 MAPT (0.59) KCNH2ACHEHTTLTA4HKMT2A
Dofetilide SCHEMBL8362214 0.63 KCNH2 (0.97) KCNH2DRD3CACNA1FCHRM2ACHE
SCHEMBL16804696 0.62 MAPT (0.58) KCNH2ACHEHTTLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025846-A1 ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS ACAD PHARMACEUTICALS INC (US) 2024-01-25 US disclosed
US-11731938-B2 Ultra short acting anti-arrhythmic agents ACADEMIC PHARMACEUTICALS INC (US) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731938-B2 Ultra short acting anti-arrhythmic agents CACNA1G, SCN5A, CACNA1F KCNH2 51/4885DRD3 534/4885CACNA1F 3/4885
US-20240025846-A1 ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS CACNA1G, SCN5A, CACNA1F KCNH2 51/4885DRD3 534/4885CACNA1F 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.